COVID-19 and the Pharmaceutical Industry

COVID-19 and the Pharmaceutical Industry [Kochański & Partners report]

3 July 2020 | Knowledge, News

International investment capital will flow to companies capable of developing a cure for COVID-19. However, the Polish pharmaceutical sector, contrary to earlier expectations, has been experiencing serious declines compared to pre-coronavirus pandemic quotations.

 Surprising declines

Although global pharmaceutical companies have responded relatively mildly to COVID-19, the Polish sector has been experiencing heavy declines, reaching 50% in mid-March, compared to the values at the beginning of the year. There are also no prospects for a rapid recovery from the crisis – by early June, the losses were reduced to 28%.

The difficult situation of Polish companies is largely due to a decrease in the number of pharmaceutical products purchased, resulting from patients limiting their visits to pharmacies and medical facilities for fear of coronavirus infection. The crisis in the sector is also fuelled by the collapse of the global supply chain, since many medical components were delivered to Poland from China and Italy.

Vaccine race

The limited potential for developing a coronavirus vaccine is one of the main causes of the crisis in the Polish pharmaceutical market. A rapid introduction of a cure for COVID-19 is one of the greatest challenges faced by the global pharmaceutical sector in the age of pandemics. The first company to reach this goal will experience a dramatic increase in revenue at previously unimagined levels. Investors around the world are thus investing heavily in those companies which they consider closest to developing the vaccine. Gilead Sciences, U.S., openly reporting on progress in vaccine development, recorded a stock market value surge at the beginning of the pandemic. However, investors had to quickly tone down their optimism. The observed change in the company’s valuation suggests that the inflow of capital is rather speculative. JP Morgan downgraded Gilead Sciences shares in early May to neutral.

U.S. and German recovery

Compared to Poland, the situation of the U.S. drug sector is quite optimistic. The pharmaceutical index was systematically recovering to reach 2.9% after falling by 24.5% in the second half of March. The positive trend is due to the high technological potential of U.S. companies, enabling them to meet the dynamically changing needs of consumers. One example may be Pfizer recording a jump in revenue from sales of a vaccine against pneumonia in recent months.

The long-term development prospects for the U.S. pharmaceutical industry will depend, however, on stabilizing relations with China, one of the United States’ main business partners.

The German pharmaceutical sector saw stock market indices reacting to the pandemic similarly to the U.S. indices, reaching the value from the beginning of the year following a decline of 28% in June. The COVID-19 pandemic, however, has exposed Germany’s strong dependence on the global supply chain – the sudden closure of borders revealed a problem with access to medicines in the local market.

 

DOWNLOAD THE REPORT

Latest Knowledge

Banking in 2026: technology, regulation and the new market landscape

The year 2026 will see the banking sector undergo its most dynamic transformation in a decade. The trends identified in Accenture’s Top Banking Trends FY26 report suggest that the sector is entering a phase in which technology and regulation will be inseparable, driving all aspects of change. However, it is regulation that determines the boundaries, pace and manner of implementation for new solutions. We take a look at what else the experts are focusing on.

The new National Cybersecurity System

The amendment to the Act on the National Cybersecurity System (UKSC) is one of the most significant regulatory reforms in recent years. Its main objective is to align Polish law with Directive (EU) 2022/2555 of the European Parliament and of the Council. The directive, also known as NIS2, substantially raises digital security requirements across the Union. The Polish Act on the National Cybersecurity System has undergone a thorough overhaul, covering more organisations (with estimates suggesting nearly 40,000 entities), introducing more demanding obligations, statutory personal liability for management board members, and even more stringent rules for imposing financial penalties. In the case of the most serious violations, these penalties can reach 100 million PLN.

‘Made in Europe’ is no longer just a slogan. It is becoming law

Until recently, ‘Made in Europe’ was just a label. While it was useful for marketing purposes, it lacked any hard, normative content. This may soon change. On 4 March, the European Commission published a proposal for the Industrial Accelerator Act, stipulating that, from 2027 onwards, the Union origin of components will be a prerequisite for participating in renewable energy auctions, accessing public funding, and for being eligible to participate in public procurement procedures. The slogan ‘Buy European’ could become a concrete instrument for supporting local production and controlling foreign investment.

Non-obvious cases of transferring an establishment to a new employer

The transfer of all or part of an establishment (zakład pracy) is a special concept in labour law relating to changes in ownership. Put simply, it is the automatic transfer of all the rights and obligations of the employer from one entity to another, without the need for any additional actions or consents from the parties involved. However, this must be preceded by the fulfilment of a range of informing obligations by both the new and former employers. Let’s take a look at what the process should involve.

Protecting yourself against tax risks in the deposit-return system

The deposit-return system has been in place since October 2025, raising significant tax concerns from the outset. Although the regulations came into force, it was unclear for a long time how to apply them in practice. Some of the regulations needed clarification, some solutions were missing and the published explanations did not cover all the key issues. Consequently, the market began to develop its own operating standards.

Banking sector overview | Banking today and tomorrow | March 2026

On 12 February 2026, the Court of Justice of the European Union (CJEU) issued a judgment concerning the use of the WIBOR index in loan agreements. The CJEU judges confirmed that, in consumer cases, courts cannot examine the correctness of the WIBOR calculation. The banks had correctly informed their clients about the reference rate in accordance with national and EU law.

The issue of the National Labour Inspectorate reform has resurfaced

A new draft law proposing changes to the way the National Labour Inspectorate operates has been submitted to the Sejm. During its first reading on 25 February, the draft was not rejected and was therefore referred to the Social Policy and Family Committee for further consideration. Despite the concerns and controversies raised so far, including by businesses, the legislature continues to pursue the thorough modernisation of Poland’s employment model, which involves increased supervision of the labour market and curbing the abuse of civil law contracts. In this article, we will take a look at the proposals included in the new draft and explain what they mean for businesses.